Participated · Series B · Nov 2025

Elephas Biosciences has built the Elephas Live™ Platform, an ex-vivo, live-tumor-profiling system that maintains a biopsy’s native tumor micro-environment while addressing tumor heterogeneity. The platform functionally characterizes immune response in real time, enabling clinicians to better predict whether a cancer patient will benefit from immunotherapy. With only one in five patients currently responding to immunotherapy, Elephas aims to raise overall response rates and expand patient eligibility by providing more accurate predictive data. The company plans to launch the platform in 2026 as a laboratory developed test (LDT) to accelerate clinical adoption. Recent additions to its Scientific Advisory Board, including Jérôme Galon, Ph.D., and Janis Taube, M.D., signal continued scientific validation efforts. Headquartered in Madison, Wisconsin, Elephas is privately held and backed by a syndicate of life-science investors. The newly secured funding will finance commercialization activities and further technology development.

Participated · Series C · Oct 2024

Rivermark Medical develops the FloStent, a minimally invasive, fully reversible urethral stent intended as a first-line device therapy for men with urinary symptoms from benign prostatic hyperplasia. The FloStent is designed for outpatient placement during routine cystoscopy using standard urology tools and can be removed or adjusted after implantation to preserve future treatment options. Rivermark reported positive results from a multicenter RAPID II study showing rapid recovery and durable benefit at 24 months. The company is conducting a pivotal RAPID III clinical trial and is pursuing U.S. regulatory approval and commercial launch. Financially, Rivermark raised $20 million in a Series D led by Andera Partners to support the pivotal trial, regulatory submissions, and launch preparations. Aneta Sottil of Andera joined the company’s board as part of the financing. The FloStent is currently an investigational device limited to experimental use under U.S. federal law.

Participated · Series D · Aug 2024

HistoSonics develops a non-invasive therapeutic platform based on histotripsy, a focused-ultrasound technology that uses acoustic cavitation to mechanically destroy and liquefy targeted tissue. Its flagship product, the Edison® Histotripsy System, received U.S. FDA De Novo clearance for the destruction of liver tumors and has seen expanding clinical adoption at academic medical centers and health systems. Use of the system outside the liver remains investigational while the company pursues regulatory clearances for additional organs. HistoSonics has submitted a De Novo request to the FDA for kidney tumors and is advancing toward an anticipated FDA submission for pancreatic applications. The company is focused on commercializing the Edison System in the U.S. and select global markets while expanding indications into kidney, pancreas, prostate and other organs. HistoSonics maintains offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN, and was valued at $3.75 billion in its most recent financing.

Led · Series B · Apr 2024

EarliTec Diagnostics is an Atlanta-based startup whose FDA-authorized system uses AI to track eye movements while a child watches short videos and social interactions to assist autism diagnosis. The tablet-based test takes about 12 minutes and targets children aged 16 to 30 months, aiming to shorten the multi-hour traditional assessment and reduce wait times. Its technology is currently used by eight clinicians across six U.S. states. The company raised new capital to expand commercialization and to fund research intended to broaden the age range it can assess and to improve assessment and treatment options. CEO Tom Ressemann emphasized the device’s flexibility to be used in clinics, schools, or at home so it can fit into existing workflows. The fresh funding will support those commercialization and research efforts. EarliTec Dx develops objective diagnostic and therapeutic products for children with Autism Spectrum Disorder using its EarliPoint® system and Dynamic Quantification of Social-Visual Engagement (DQSVE). The EarliPoint Evaluation is an investigational device that captures moment-by-moment looking behavior at 120 Hz while a child watches videos and compares each data point to a clinically validated database. The technology was developed with researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University, and the company has completed clinical trials with more than 1,500 children. EarliTec received FDA breakthrough designation for the EarliPoint system in April of last year. The company plans to seek FDA 510(k) clearance, commercialize the EarliPoint system, and expand its digital biomarkers built on a proprietary multimodal AI platform. A recent $19.5 million financing will fund regulatory filing, commercialization, and further development.

Participated · Series C · Apr 2024

ViaLase is a clinical-stage medical technology company based in Aliso Viejo, CA focused on addressing unmet needs in the conventional glaucoma treatment paradigm. Its core product is the investigational ViaLase Laser, which combines femtosecond laser technology and micron-level image guidance to deliver a noninvasive procedure called femtosecond laser image-guided high-precision trabeculotomy (FLigHT). The FLigHT procedure creates channels in the trabecular meshwork to lower intraocular pressure through a noninvasive, nonsurgical approach, providing physicians with precision and visibility. The company is led by founder and CEO Tibor Juhasz, PhD. ViaLase intends to use recent financing to advance clinical, regulatory, and commercial milestones for the ViaLase Laser; the device is investigational and not approved for commercial use.